argenx (ARGX) Stock Forecast & Price Target

Argenx demonstrated substantial revenue growth during the first half of 2025, reporting $790 million in Q1 (an increase of 98% year-over-year) and $949 million in Q2 (up 97% year-over-year), primarily fueled by the strong adoption of the pre-filled syringe (PFS) format and increased uptake of Vyvgart in various therapeutic lines, including generalized myasthenia gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company has also successfully expanded its prescriber base, with approximately 1,000 PFS prescribers, including 150 new prescribers who were previously unfamiliar with Vyvgart, indicating robust market acceptance and potential for continued growth. Additionally, ongoing label expansion opportunities and positive results for indications such as ocular myasthenia gravis further enhance Argenx’s prospects for long-term revenue generation and market penetration.

Argenx may face significant financial challenges due to the inherent risks associated with drug approval processes, where any failure or delays could substantially lower the company’s share price. The competitive landscape for autoimmune and oncologic diseases is intensifying, with numerous companies pursuing similar drug indications, which could hinder Argenx's market penetration and sales potential for its lead product, Vyvgart. Furthermore, their projections for achieving a 24% penetration rate within the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient population highlight the potential limitations in capturing market share, thus raising concerns about long-term revenue growth.